Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)

Simon Couillard; William Il Hoon Do; Richard Beasley; Timothy S C Hinks; Ian D Pavord

doi:10.1183/23120541.00570-2021

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)

ERJ Open Res. 2021 Feb 7;8(1):00570-2021. doi: 10.1183/23120541.00570-2021. eCollection 2022 Jan.

Authors

Simon Couillard^{1

2}, William Il Hoon Do¹, Richard Beasley³, Timothy S C Hinks¹, Ian D Pavord¹

Affiliations

¹ Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
² Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
³ Medical Research Institute of New Zealand, Wellington, New Zealand.

Abstract

The prototype ORACLE scale based on two simple measures of type 2 airway inflammation (blood eosinophils and F _ENO) quantifies the excess risk conferred by raised biomarkers that is removed by type-2 anti-inflammatory treatment in trial populations https://bit.ly/3F1gnUl.

Abstract

Grants and funding